Key player · Company profile

UCB S.A.

Named as a key player in 66 of our reports, across 33 regions and countries.

Fastest-growing markets they play in

2023–2033 CAGR · estimates

  1. 1Epilepsy Drugs (India) 6.5%

Where they show up

  • Pharmaceuticals66

Geographies

UCB S.A.'s markets

Markets where UCB S.A. is a key player, with the world market size
MarketCategoryWorld 2023CAGR
Epilepsy Drugs Pharmaceuticals$9.6 Bn3.5%
Axial Spondyloarthritis (axSpA) Pharmaceuticals––

Companies they compete with most

Named as key players in the same markets as UCB S.A. (number of shared markets).

Novartis AG2 shared markets Pfizer Inc.2 shared markets Abbott Laboratories1 shared market AbbVie Inc.1 shared market Amgen Inc.1 shared market Bausch Health Companies Inc.1 shared market Eisai Co.1 shared market Eli Lilly and Company1 shared market

Recent reports naming UCB S.A.

Search all reports for UCB S.A. All companies